AMAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation

Blood

Volumn 107, Issue 6, 2006, Pages 2507-2516

  Notari, Mario ^b   Neviani, Paolo ^b   Santhanam, Ramasamy ^b   Blaser, Bradley W ^b   Chang, Ji Suk ^b   Galietta, Annamaria ^b   Willis, Anne E ^b   Roy, Denis C ^b   Caligiuri, Michael A ^b   Marcucci, Guido ^b   Perrotti, Danilo ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; CD34 ANTIGEN; HNRPK PROTEIN, HUMAN; MYC PROTEIN, HUMAN; RIBONUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL CRISIS; BONE MARROW CELL; CARCINOGENESIS; CD34 SELECTION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE FUNCTION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA TRANSLATION; TRANSCRIPTION REGULATION; CELL CULTURE; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANTIGENS, CD34; BLAST CRISIS; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MYC; RIBONUCLEOPROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 33644755496     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3732     Document Type: Article

References (55)

1. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004;22:247-306.
2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
4. Arlinghaus R, Sun T. Signal transduction pathways in Bcr-Abl transformed cells. Cancer Treat Res. 2004;119:239-270.
5. Gingras AC, Raught B, Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol. 2004;279:169-197.
6. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res. 2003;63:5716-5722.
7. Perrotti D, Turturro F, Neviani P. BCR/ABL, mRNA translation and apoptosis. Cell Death Differ. 2005;6:534-540.
8. Gaiger A, Henn T, Horth E, et al. Increase of bcrabl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86:2371-2378.
9. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol. 2000;79:424-431.
10. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-667.
11. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30:48-58.
12. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 2003;3:145-160.
13. Makeyev AV, Liebhaber SA. The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA. 2002;8:265-278.
14. Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. Bioessays. 2004;26:629-638.
15. Lee MH, Mori S, Raychaudhuri P. trans-Activation by the hnRNP K protein involves an increase in RNA synthesis from the reporter genes. J Biol Chem. 1996;271:3420-3427.
16. Michelotti EF, Michelotti GA, Aronsohn AI, Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol. 1996;16:2350-2360.
17. Taylor SJ, Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature. 1994;368:867-871.
18. Bustelo XR, Suen KL, Michael WM, Dreyfuss G, Barbacid M. Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins. Mol Cell Biol. 1995;15:1324-1332.
19. Groysman M, Nagano M, Shaanan B, Katzav S. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation. Oncogene. 1998;17:1597-1606.
20. Schullery DS, Ostrowski J, Denisenko ON, et al. Regulated interaction of protein kinase Cdelta with the heterogeneous nuclear ribonucleoprotein K protein. J Biol Chem. 1999;274:15101-15109.
21. Habelhah H, Shah K, Huang L, et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol. 2001;3:325-330.
22. Ostareck-Lederer A, Ostareck DH, Cans C, et al. c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol. 2002;22:4535-4543.
23. Evans JR, Mitchell SA, Spriggs KA, et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene. 2003;22:8012-8020.
24. Iervolino A, Santilli G, Trotta R, et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol. 2002;22:2255-2266.
25. Tenenbaum SA, Lager PJ, Carson CC, Keene JD. Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. Methods. 2002;26:191-198.
26. Cheng M, Wang D, Roussel MF. Expression of c-Myc in response to colony-stimulating factor-1 requires mitogen-activated protein kinase kinase-1. J Biol Chem. 1999;274:6553-6558.
27. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910.
28. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993;21:1460-1466.
29. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333-2342.
30. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood. 1996;88:1005-1012.
31. Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24:6432-6440.
32. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABLmediated leukemogenesis. EMBO J. 1998;17:4442-4455.
33. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;5:355-368.
34. Mandal M, Vadlamudi R, Nguyen D, et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem. 2001;276:9699-9704.
35. Nagano K, Masters JR, Akpan A, et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene. 2004;23:1693-1703.
36. Harris MN, Ozpolat B, Abdi F, et al. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 2004;104:1314-1323.
37. Urbani A, Poland J, Bernardini S, et al. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics. 2005;5:796-804.
38. Skorski T, Nieborowska-Skorska M, Szczylik C, et al. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res. 1995;55:2275-2278.
39. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood. 2004;103:3167-3174.
40. Li S, Couvillon AD, Brasher BB, Van Etten RA. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 2001;20:6793-6804.
41. Michael WM, Eder PS, Dreyfuss G. The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO J. 1997;16:3587-3598.
42. Di Cristofano A, Niki M, Zhao M, et al. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med. 2001;194:275-284.
43. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. The SH3 domain contributes to BCR/ABLdependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood. 1998;91:406-418.
44. Blick M, Romero P, Talpaz M, et al. Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987;27:349-356.
45. Gopal V, Kadam P, Preisler H, et al. Abnormal regulation of the myc gene in myeloid leukemia. Med Oncol Tumor Pharmacother. 1992;9:139-147.
46. Preisler HD, Sato H, Yang PM, Wilson M, Kaufman C, Watt R. Assessment of c-myc expression in individual leukemic cells. Leuk Res. 1988;12:507-516.
47. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci U S A. 1996;93:13137-13142.
48. Sawyers CL. The role of myc in transformation by BCR-ABL. Leuk Lymphoma. 1993;11(suppl 1):45-46.
49. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21:7137-7146.
50. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
51. Eisbruch A, Blick M, Evinger-Hodges MJ, et al. Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer. 1988;62:1171-1178.
52. Ohmine K, Ota J, Ueda M, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene. 2001;20:8249-8257.
53. Gribble SM, Reid AG, Roberts I, Grace C, Green AR, Nacheva EP. Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation. Genes Chromosomes Cancer. 2003;37:346-358.
54. Karasawa M, Okamoto K, Maehara T, et al. Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes. Leuk Res. 1996;20:85-91.
55. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia. 1996;10:751-756.